当前位置: 首页 >> 检索结果
321. Progression of Pancreatic Morphologic Changes and Endocrine Dysfunction After Acute Pancreatitis: Preliminary Results of the Longitudinal Goulash-Plus Cohort Study.
作者: Alexandra Mikó.;Nelli Farkas.;Áron Vincze.;Ferenc Izbéki.;Andrea Szentesi.;Péter Hegyi.; .
来源: Gastroenterology. 2026年170卷3期631-634页 322. Characteristics of Colonoscopy- and Fecal Immunochemical Test-Based Screen-Detected Premalignant Neoplastic Lesions: Results From the COLONPREV Study.
作者: Antoni Castells.;Enrique Quintero.;Maria Pellisé.;Eladio Frías-Arrocha.;Cristina Hernández.;Miquel Serra-Burriel.; .
来源: Gastroenterology. 2026年170卷3期627-630页 324. Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.
作者: Grishma Hirode.;Hooman F Zangneh.;Orlando Cerocchi.;Korosh Khalili.;Lima A El-Karim.;Christopher Kandel.;Mara Vecchio.;Jeffrey Winick.;Yasuhiro Mori.;Hiroyuki Yamada.;Harry L A Janssen.;Bettina E Hansen.;Morris Sherman.;Jordan J Feld.
来源: Gastroenterology. 2026年170卷3期595-605页
Hepatocellular carcinoma (HCC) surveillance is key to early diagnosis and timely curative treatment. Current strategies are suboptimal with many patients presenting with advanced HCC. This randomized controlled trial compared the combined use of serum biomarker (BM) measurements and abdominal ultrasound (US) with US alone for the diagnosis of early-stage HCC.
325. Metabolic liver disease research in the Arab world: a bibliometric analysis of trends, collaborations, and disparities (2006-2024).
作者: Mortada H El-Shabrawi.;Maito Suoh.;Shadan Almuhaidib.;Saleh A Alqahtani.;Sameer Al Awadhi.;Said A Al-Busafi.;Maheeba Abdulla.;Yasser Fouad.;Maisam Akroush.;Mohamed Tahiri.;Munira Y Altarrah.;Mohammed Eslam.
来源: Minerva Gastroenterol (Torino). 2026年72卷1期37-50页
Non-alcoholic fatty liver disease (NAFLD), which has recently been renamed metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease globally, including in the Arab world. This study investigates the research output and impact of NAFLD/MAFLD/MASLD in Arab countries until 2024.
326. Assessment of the impact of furosemide use on outcomes in patients with intra-abdominal hypertension: a retrospective cohort study from the MIMIC-IV database.
作者: Jing Wang.;Xiaojie Zhang.;Ziyue Wang.;Zixuan Wang.;Ye Yin.;Jiaqi Li.;Yu Wei.;Qingling Feng.;Xin Hang.;Yurong Wang.;Fei Wu.;Le Xia.;Min Zhu.;Yan Xiao.;Xiaohong Liu.;Jinqiang Zhuang.
来源: BMC Gastroenterol. 2026年26卷1期121页
This study aims to explore the effect of furosemide on the prognosis of patients with intra-abdominal hypertension (IAH).
327. Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma treated with TACE combined with systemic therapy.
作者: Guobin Chen.;Meixia Wang.;Xing Huang.;Zhenzhen Zhang.;Yanfang Wu.;Xiaochun Chen.;Xinkun Guo.;Susu Zheng.;Tanghui Zheng.;Hong Chen.;Jingfang Wu.;Boheng Zhang.
来源: BMC Gastroenterol. 2026年26卷1期119页
Tumor growth rate (TGR) is a dynamic biomarker for evaluating therapeutic response and prognosis in unresectable hepatocellular carcinoma (uHCC) with triple therapy, yet its clinical utility and role in guiding treatment optimization require further validation.
328. Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
作者: Camille Danne.;Rodrigo de Oliveira Formiga.;Laura Creusot.;Florian Marquet.;Delphine Sedda.;Laura Hua.;Pauline Ruffié.;Hang-Phuong Pham.;Loic Brot.;Iria Alonso Salgueiro.;Marie-Laure Michel.;Philippe Langella.;Jérémie H Lefevre.;Harry Sokol.;Nathalie Rolhion.
来源: Gastroenterology. 2026年170卷4期704-720页
Faecalibacterium prausnitzii, a highly abundant gut bacterium, has been linked to overall health, and is decreased in several pathologic conditions, such as inflammatory bowel disease (IBD). F prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of interleukin 10 (IL10) signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL10 induced by F prausnitzii and provide the first mechanistic insights.
329. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer.
作者: Zhilong Ma.;Mingwei Dong.;Haoqi Pan.;Junyi Xu.;Tingyi Luo.;Wangcheng Xie.;Mingming Xiao.;Xin Wen.;Jie Hua.;Daohai Qian.;Qingcai Meng.;Yufeng Wang.;Di Wu.;Xiaobing Zhang.;Tingsong Yang.;Zhenshun Song.;Wei Wang.;Jin Xu.;Xianjun Yu.;Si Shi.
来源: Gastroenterology. 2026年170卷4期735-752页
Patients with chronic pancreatitis (CP) have a higher risk of developing pancreatic ductal adenocarcinoma (PDAC). Although pancreatitis has been found to promote PDAC initiation and progression, its role in PDAC tumorigenesis remains poorly understood.
330. Association Between Serrated Polyps on Index Examination and Advanced Findings Detected on the Second Surveillance Colonoscopy: Data From the New Hampshire Colonoscopy Registry.
作者: Obaida Dairi.;Joseph C Anderson.;Christopher I Amos.;William Hisey.;Todd A Mackenzie.;Lynn F Butterly.; .
来源: Gastroenterology. 2026年 332. Intestinal transcriptomic analysis and prediction of biomarkers associated with mucosal healing following vedolizumab treatment in ulcerative colitis using machine learning.
作者: Katsuyoshi Ando.;Shin Kashima.;Aki Sakatani.;Hiroaki Konishi.;Atsuo Maemoto.;Takahiro Ito.;Masaki Taruishi.;Kaori Ishiguro.;Mikihiro Fujiya.
来源: BMC Gastroenterol. 2026年26卷1期117页
There is an increasing need for predictors of clinical outcomes in patients with ulcerative colitis (UC). In this exploratory analysis, we aimed to analyze the gene expression profile of intestinal tissues according to treatment outcome in patients with UC treated with vedolizumab and to develop a treatment outcome prediction model.
333. Endoplasmic reticulum stress enhances unsaturated fatty acid-induced hepatocyte injury in human pluripotent stem cell-derived hepatic culture.
作者: Takuma Araki.;Keiko Yokoyama.;Kinuyo Ida.;Yutaka Inagaki.;Akihide Kamiya.
来源: BMC Gastroenterol. 2026年26卷1期118页
The liver is a central organ involved in lipid metabolism. Hepatocytes synthesize fatty acids and triglycerides under conditions of excess energy while decomposing fats by β-oxidation under conditions of energy deficiency. When fatty acid metabolism is impaired due to metabolic syndrome, excessive lipid accumulation in the liver increases the risk of fatty liver disease, chronic hepatitis, and liver cancer. Excessive fat accumulation causes various types of cell damage, such as oxidative stress, which causes lipotoxicity. There is a difference in lipotoxicity between saturated and unsaturated fatty acids among various fatty acids, and saturated fatty acids are more toxic. However, there are still many unknowns about the role of unsaturated fatty acids in steatohepatitis remains unclear.
334. Acute oesophageal necrosis: single centre experience.
作者: Şehmus Ölmez.;Duran Deha Çetin.;Mustafa Harı.;Abdullah İlhan.;Bünyamin Sarıtaş.
来源: BMC Gastroenterol. 2026年26卷1期115页
Acute oesophageal necrosis (AEN) is a rare but important cause of upper gastrointestinal bleeding (UGIB). The prognosis is poor and related to the presence of concomitant diseases. In this study, we aimed to evaluate the outcomes of patients with AEN.
335. An interpretable machine learning model for prediction of significant liver fibrosis in comorbid chronic hepatitis B and nonalcoholic fatty liver disease: a retrospective development and validation study.
The coexistence of chronic hepatitis B (CHB) and nonalcoholic fatty liver disease (NAFLD) accelerates liver fibrosis progression, but effective noninvasive tools for fibrosis risk assessment in this specific population are lacking. This study aimed to develop and validate an explainable machine learning (ML) model to predict significant liver fibrosis in patients with comorbid CHB and NAFLD.
336. Shared and distinct spontaneous brain activity pattern in crohn's disease and ulcerative colitis: evidence from cortical surface‑based analysis.
作者: Mengting Huang.;Qinyue Luo.;Shuo Huang.;Yuting Zheng.;Yimeng He.;Liangru Zhu.;Ping Han.;Jiawei Wu.;Heshui Shi.
来源: BMC Gastroenterol. 2026年26卷1期112页
Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD), are associated with emotional disturbances, but their shared and distinct neurobiological substrates remain unclear. This neuroimaging study aimed to characterize shared and distinct patterns of spontaneous neural activity in CD and UC patients using resting-state functional MRI (rs-fMRI).
337. Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice.
作者: Yoshinori Ozono.;Hiroshi Kawakami.;Hiroshi Hatada.;Naomi Uchiyama.;Souichiro Ogawa.;Keisuke Uchida.;Hotaka Tamura.;Yuri Komaki.;Kenichi Nakamura.;Hisayoshi Iwakiri.;Satoru Hasuike.;Kenji Nagata.
来源: BMC Gastroenterol. 2026年26卷1期108页
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a sodium-glucose cotransporter type-2 inhibitor, is widely used in patients with type 2 diabetes. Several clinical trials with Tofo have shown its beneficial effects in NAFLD patients with diabetes; however, currently, there are limited data on NAFLD patients without diabetes.
338. Targeted therapies and their outcomes in monogenic very early onset inflammatory bowel disease: a systematic review.
作者: Amir Parsa Abhari.;Parastesh Rezvanian.;Elika Sohrabi.;Kaveh Hosseini.;Mohamed Attauabi.;Rashee Gupta.;Kimia Najafi.
来源: BMC Gastroenterol. 2026年26卷1期113页
Very early onset inflammatory bowel disease (VEO-IBD) is a rare, severe condition with over 80 monogenic causes. These often resist conventional therapies, necessitating targeted treatments such as biologics and hematopoietic stem cell transplantation (HSCT). This study aimed to systematically review therapeutic outcomes.
339. Comparison of diagnostic value of abdominal obesity and metabolism-related indicators for non-alcoholic fatty liver disease in lean individuals.
作者: Hailong Zhang.;Meng Guo.;Xiao Liang.;Dan Wan.;Chunli Zhang.;Fanfan Liang.;Sijia Chen.;Qian Wang.;Zongfang Li.
来源: BMC Gastroenterol. 2026年26卷1期111页
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease globally. The present study aims to investigate the diagnostic value of abdominal obesity and metabolism-related indicators for NAFLD in lean individuals.
340. A 7-cm inflection point: nonlinear association between maximum tumor diameter and capsular invasion risk after primary liver cancer resection.
作者: Ye Zhang.;Gongming Zhang.;Xin Wang.;Yingmin Ma.;Guangming Li.
来源: BMC Gastroenterol. 2026年26卷1期114页
Capsular invasion independently predicts poor prognosis after primary liver cancer (PLC). While maximum tumor diameter (MTD) informs staging systems, its potential nonlinear association with capsular invasion remains unquantified.
|